drugset / Trial / NCT04166006
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Phase 2
Recruiting
51 enrolled
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NaSingle-groupOpen-labelTreatment
Summary
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head/Neck tumors (H\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).
Timeline
- Start
- 2019-12-12
- Primary completion
- 2027-04
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | 7e+06 cells | Intramuscular |
| Subject | DC vaccine | Vaccine | 1.4e+07 cells | Intramuscular |
| Background | aldesleukin | Protein / enzyme biologic | 3e+06 iu | Subcutaneous |